The benefits of adefovir dipivoxil for HBeAg-negative chronic hepatitis B did not persist after discontinuation of treatment

January 2006
ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p4
Academic Journal
This article reports on a study conducted to examine the efficacy of adefovir dipivoxil in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. 120 patients with HBeAg-negative chronic hepatitis B and compensated liver disease, who had received treatment with adefovir dipivoxil during the previous 48 weeks as part of a randomized placebo-controlled trial were studied. At the end of the second 48 weeks, the decreased levels were maintained in the adefovir group, but not in the placebo group, in which reversion to near-baseline values occurred within 4 to 8 weeks of switching to placebo.


Related Articles

  • Long-term lamivudine benefits children with hepatitis B.  // Nursing Standard;2/13/2008, Vol. 22 Issue 23, p15 

    The article reports on the result of the study concerning the utilization of lamivudine in the treatment of children suffering from chronic hepatitis B. It was conducted through a randomized trial study which was participated by 151 children and were administered with lamivudine and placebo for...

  • Comparison of Two Recombinant Hepatitis B Vaccines. Nejad, Hasan Nikui; Ghorbani, Gholamali; Razaghi, Reza; Akbari, Hossain // Hepatitis Monthly;Summer2009, Vol. 9 Issue 3, p201 

    Background and Aims: Hepatitis B virus (HBV) infection is an important public health problem. Hepatitis B vaccine induces protective response in the majority of vaccinated persons. In our country, we do not have any evaluation for the efficacy of each type of vaccines used in adult and our...

  • HEPATITIS B. Kassianos, George // Pulse;12/10/2005, Vol. 65 Issue 48, p43 

    The article presents the author's view on Hepatitis B. George Kassianos shares his insights gained from working as a general practitioner. He informed that tattoos and piercing, plus sharing of personal items such as tooth brushes, razors and earrings can all lead to exposure to infected blood...

  • HEPATITIS B AND RENAL TRANSPLANTATION: DANGLING THE SWORD OF DAMOCLES? Ryan, Michael J.; Johnson, David A.; Cattau Jr., Edward L. // American Journal of Gastroenterology;Dec1992, Vol. 87 Issue 12, p1882 

    Comments on a study on the increased risk of fatal liver disease in renal transplant patients who are hepatitis B antigen and/or hepatitis B virus DNA positive by Fairley C. R. et al, published in a 1991 issue of "Transplantation." Abstract of the study; Key findings; Criticisms.

  • Mortality Secondary to Fulminant Hepatic Failure in Patients with Prior Resolution of Hepatitis B Virus Infection in Japan. Umemura, Takeji; Tanaka, Eiji; Kiyosawa, Kendo; Kumada, Hiromitsu // Clinical Infectious Diseases;9/1/2008, Vol. 47 Issue 5, pe52 

    Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection was found in 23 (4%) of 552 newly hepatitis B surface antigen-positive patients in Japan. Because onefourth of cases develop into fulminant hepatic failure and mortality is 100%, management of HBV reactivation in...

  • The Prevention of Hepatitis B with Vaccine. Francis, Donald P.; Hadler, Stephen C.; Thompson, Sumner E.; Maynard, James E.; Ostrow, David G.; Altman, Norman; Braff, Erwin H.; O'Malley, Paul; Hawkins, Donald; Judson, Franklyn N.; Penley, Kent; Nylund, Thom; Christie, Graham; Meyers, Frank; Moore Jr., Joseph N.; Gardner, Ann; Doto, Irene I.; Miller, Joe H.; Reynolds, Gladys H. // Annals of Internal Medicine;Sep82, Vol. 97 Issue 3, p362 

    Presents information on a randomized placebo trial of the Merck hepatitis B virus (HBV) vaccine among homosexual men attending venereal disease clinics in the U.S. Details on HBV infections in humans; Materials and methods used in the study; Results.

  • Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Yeon, J. E.; Yoo, W.; Hong, S. P.; Chang, Y. J.; Yu, S. K.; Kim, J. H.; Seo, Y. S.; Chung, H. J.; Moon, M. S.; Kim, S.-O.; Byun, K. S.; Lee, C. H. // Gut;Oct2006, Vol. 55 Issue 10, p1488 

    Background: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV). The cumulative incidence of ADV resistant mutations in the nucleoside/-tide treatment naïve chronic hepatitis B patient (CHB) at weeks 48,...

  • Autoimmune Factors in African Cirrhosis. Sadikali, F.; Doniach, D. // American Journal of Gastroenterology;Dec1975, Vol. 64 Issue 6, p484 

    Sera were tested for autoantibodies in 98 patients with cryptogenic cirrhosis in Uganda and results correlated with serological tests for hepatitis B surface antigen (HBs Ag) and antibody to HBs Ag (HBs Ab). Smooth muscle antibodies (SMA) were detected in 23 (24%) of the patients but there was...

  • Anti-HBV Drugs: Progress, Unmet Needs, and New Hope. Lei Kang; Jiaqian Pan; Jiaofen Wu; Jiali Hu; Qian Sun; Jing Tang // Viruses (1999-4915);2015, Vol. 7 Issue 9, p4960 

    Approximately 240 million people worldwide are chronically infected with hepatitis B virus (HBV), which represents a significant challenge to public health. The current goal in treating chronic HBV infection is to block progression of HBV-related liver injury and inflammation to end-stage liver...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics